NASDAQ$PHVS
Pharvaris NV · Q2 2026 earnings
Q2 2026 earnings · · After market close · Investor relations
Briefing
Pharvaris NV reported second quarter 2026 financial results on August 12, 2026, showing a net loss of €47.8 million.
The clinical-stage biopharmaceutical company reported increased R&D and G&A expenses leading to a wider quarterly net loss compared to the prior year. Cash position strengthened to €318 million following a recent financing. Pipeline progress continued with regulatory reviews underway and pivotal data expected later in the year.
- Net loss of €47.8 million (€0.70 per share) for Q2 2026, compared to €45.5 million (€0.83 per share) in Q2 2025.
- R&D expenses rose to €35.0 million from €29.6 million year-over-year.
- G&A expenses increased to €15.8 million from €10.8 million year-over-year.
- Cash and cash equivalents reached €318 million as of June 30, 2026, up from €292 million at year-end 2025.
Headline financials
Revenue & EPS history
Pharvaris · Revenue · Quarterly
€0
Forward guidance
Company expects topline data from CHAPTER-3 Phase 3 study in 3Q2026; NDA under FDA review with PDUFA date April 23, 2027; cash runway extended into 2028.
Tailwinds
- Strong cash position supports launch preparation and pipeline advancement.
- Regulatory progress on deucrictibant IR with FDA and EMA reviews underway.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports
+16.7%
Avg return
Earnings day
+16.1%
Avg return
5 days after
+27.4%
Avg return
30 days after
36%
5 / 14 earnings
Positive
+243.4%
Q3 2022
Best reaction
-10.4%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -0.4% | +1.5% | +7.3% | |
| Q3 2025 | +7.3% | +3.3% | +0.2% | |
| Q4 2024 | -10.4% | -9.2% | +29.0% | |
| Q3 2024 | +3.6% | +5.4% | -7.3% | |
| Q4 2023 | -3.6% | -12.9% | -7.3% | |
| Q3 2023 | +9.3% | +2.7% | +9.9% | |
| Q2 2023 | -3.9% | -1.4% | +11.6% | |
| Q4 2022 | -5.2% | -2.0% | +9.0% | |
| Q3 2022 | +243.4% | +241.4% | +376.1% | |
| Q2 2022 | -2.7% | -2.1% | -46.3% | |
| Q4 2021 | -0.8% | -0.4% | -1.1% | |
| Q3 2021 | -0.2% | -0.8% | -6.8% | |
| Q2 2021 | -2.4% | -1.8% | +18.0% | |
| Q1 2021 | +0.0% | +1.2% | -8.7% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro